Low-dose direct oral anticoagulants were associated with a significantly higher risk of thromboembolic events (HR 1.29) and death (HR 1.52) compared to phenprocoumon in patients with atrial fibrillation.
Cohort (n=41,903)
Does low-dose DOAC therapy improve thromboembolic events, death, and major bleeding compared to phenprocoumon in patients with atrial fibrillation?
In a real-world German cohort, phenprocoumon was associated with significantly fewer thromboembolic events and deaths compared to low-dose DOACs in patients with atrial fibrillation.
Effect estimate: HR 1.29 (95% CI 1.13-1.48)
Absolute Event Rate: 4.42% vs 2.53%
p-value: p=<0.001
BACKGROUND: For stroke prevention in patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists (VKA). For some patients a lower dosage of DOACs (ld-DOACs) is recommended. Ld-DOAC prescribing seems to be common, although previous studies did not show clear superiority of ld-DOACs over warfarin. In Germany, phenprocoumon is used almost exclusively as VKA. Randomized controlled trials comparing DOACs and phenprocoumon in the general population of patients with AF do not exist. Therefore, we aimed to compare ld-DOACs and phenprocoumon in a real-world setting in Germany. METHODS: In a retrospective observational cohort study, claims data from a group of small to medium-sized health insurance companies were analysed. Risks for the outcomes thromboembolism, death and major bleeding were estimated by Cox regression. Out of 93,685 patients with atrial fibrillation and a first prescription of an oral anticoagulant, 20,179 receiving VKA and 21,724 ld-DOACs (29.6% of all DOAC patients) were included. For the sensitivity analysis phenprocoumon was compared to the five ld-DOAC groups (ld-apixaban, ld-dabigatran, ld-edoxaban, ld-rivaroxaban, and the composite of all ld-DOACs) after propensity-score matching. RESULTS: Phenprocoumon was associated with statistically significant fewer thromboembolic events (HR = 1.29, 95% CI 1.13, 1.48, p < .001) and deaths (HR = 1.52, 95% CI 1.41, 1.63, p < .001) and a non-significant higher bleeding risk (HR = 0.89, 95% CI 0.79, 1.00, p = .051) than composite ld-DOAC. Regarding the subgroups, only patients with ld-apixaban had a statistically significant higher risk for thromboembolic events (HR = 1.42, 95% CI 1.21, 1.65, p < .001) and a lower bleeding risk (HR = 0.75, 95% CI 0.65, 0.86, p < .001). Ld-apixaban, ld-edoxaban, and ld-rivaroxaban were associated with a higher risk of death. The sensitivity analysis confirmed these associations. CONCLUSION: Phenprocoumon seems to be superior to ld-DOACs for patients with AF. As a hypothesis phenprocoumon might turn out to be the wiser choice for high-risk patients with AF as compared to ld-DOACs, especially regarding thromboembolic events and death. Therefore, RCTs comparing ld-DOACs with phenprocoumon are needed.
Warkentin et al. (2022) conducted a cohort in Atrial fibrillation (n=41,903). Low-dose direct oral anticoagulants (ld-DOACs) vs. Phenprocoumon was evaluated on Thromboembolic events (HR 1.29, 95% CI 1.13-1.48, p=<0.001). Low-dose direct oral anticoagulants were associated with a significantly higher risk of thromboembolic events (HR 1.29) and death (HR 1.52) compared to phenprocoumon in patients with atrial fibrillation.